Identification of Biomarkers for Early Detection of Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00897494|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : March 9, 2016
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer.
|Condition or disease||Intervention/treatment|
|Pancreatic Cancer||Genetic: protein expression analysis Other: laboratory biomarker analysis Other: mass spectrometry Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
- Identify specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer.
- Analyze serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis.
OUTLINE: Blood from patients is collected prior to treatment. Plasma proteins are analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS) and/or electrospray mass spectrometry (ESI/MS).
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||75 participants|
|Official Title:||Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project|
|Study Start Date :||February 2005|
|Actual Primary Completion Date :||November 2009|
|Actual Study Completion Date :||April 2011|
Genetic: protein expression analysis
- Identification of specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer [ Time Frame: Upon collection when patient agrees to provide a one time venous blood collection ]
- Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis [ Time Frame: After separation from the plasma ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00897494
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Principal Investigator:||Fazlul Sarkar, MD||Barbara Ann Karmanos Cancer Institute|